Enterprise Value
2.223B
Cash
702M
Avg Qtr Burn
N/A
Short % of Float
11.03%
Insider Ownership
12.80%
Institutional Own.
90.19%
Qtr Updated
12/31/23
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Anito-cel (anitocabtagene autoleucel)(CART-ddBCMA) Details Multiple myeloma, Cancer | Phase 2 Data readout | |
ACLX-002 (ARC-SparX program) Details Myelodysplastic syndrome, Acute myeloid leukemia, Cancer | Phase 1 Data readout | |
ACLX-001 (ARC-SparX program) Details Multiple myeloma, Cancer | Phase 1 Update |